Business context and reporting period
The supplied filing is Immudyne, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2015—not a LifeMD, Inc. filing. Immudyne develops and sells yeast beta-glucan immune-support products for oral and topical use. The company reported increased product demand and said it planned to launch a skin-care regimen with a third party in the fourth quarter of 2015.
Financial performance and position
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Sales | $279,884 | $165,469 | $845,513 | $554,509 |
| Gross profit | $205,896 | $93,864 | $607,806 | $364,658 |
| Gross margin | 74% | 57% | 72% | 66% |
| Operating income (loss) | $17,941 | $(132,945) | $8,605 | $(385,960) |
| Net income (loss) | $8,119 | $(103,904) | $(11,243) | $(316,348) |
| Operating cash flow | Not presented by quarter | $(80,311) | $7,948 |
At September 30, 2015, cash was $73,862; current assets were $245,015 and current liabilities were $381,856, giving negative working capital of $136,841 and a 0.6:1 current ratio. Notes payable totaled $106,478, including $75,000 owed to a shareholder and $31,478 to a commercial lender. Total assets were $245,015 and stockholders’ deficit was $136,841. The filing reports no quarterly cash-flow figures.
Material changes versus comparable periods
- Q3 sales rose 69% year over year; nine-month sales increased 52%. Management attributed growth primarily to higher demand.
- Gross margin improved to 74% for Q3 and 72% year to date, which management attributed partly to economies of scale.
- Q3 operating expenses fell 17%, and the company returned to quarterly net income. For the nine-month period, the net loss narrowed substantially from 2014, but remained a loss.
- Nine-month operating cash flow shifted from a $7,948 inflow to an $80,311 outflow. Cash declined by $1,633 from year-end 2014, while receivables increased to $131,724 from $14,970.
- Interest expense increased materially; nine-month 2015 interest expense was $33,048 versus $1,165 a year earlier. Q3 interest expense included $8,500 related to stock options.
Outlook, risks, contingencies and unusual items
- Going concern and financing: The filing says the accumulated deficit was approximately $8.5 million, cash flows had been negative, and substantial doubt existed about the company’s ability to continue as a going concern. Management expected to need additional capital for 2015 and 2016 and cited increased sales, equity issuance or debt financing as possible sources; no financing was assured.
- Customer concentration: One customer represented 81% of Q3 sales and 83% of nine-month sales, and 100% of accounts receivable at September 30, 2015. A second customer contributed 13% of nine-month sales.
- Debt and related-party exposure: The $75,000 shareholder note bears 5% interest, is payable upon specified financial conditions, and is convertible at the holder’s option at $0.17 per share. A separate commercial loan required 252 daily payments of $492. The president has a 60% interest in royalties payable under an agreement and deferred payment until the company has financial capacity.
- Other commitments: Royalties on certain skin-care sales reached the $227,175 contractual cap during Q2 2015; $141,448 remained accrued at September 30. The Kentucky plant lease runs through May 2016, with $28,125 of disclosed minimum base rent remaining.
- Business risks and plans: Management cited intellectual-property protection, possible tighter product regulation, and costs for marketing, equipment and studies as factors that could affect results. An October 2015 marketing agreement provided for an initial 33% equity interest and 51% voting interest in a skin-care joint venture.
- Controls: Management concluded disclosure controls were ineffective, citing material weaknesses including insufficient segregation of duties, accounting policies, IT access controls and disaster recovery, and the absence of a written whistleblower policy.
- The filing reported no known legal proceedings expected to have a material adverse effect and no material off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm issuer identity: this source is an Immudyne, Inc. filing, despite the request metadata naming LifeMD, Inc.
- Assess the company’s ability to raise capital and meet obligations, given negative working capital, operating cash outflow and the going-concern warning.
- Verify customer retention, receivable collection and the commercial terms of the highly concentrated customer relationships.
- Review the repayment and conversion terms of outstanding notes, accrued royalties and related-party interests.
- Confirm progress and expected economics of the planned skin-care launch and joint venture, and remediation of the disclosed control weaknesses.